Non-viral delivery 4basebio’s Hermes non-viral delivery system offers targeted nanoparticle vectors, presenting a prime opportunity to position solutions for customers seeking safer, non-viral gene therapy and vaccine delivery options to improve safety profiles and regulatory appeal.

Custom DNA tooling The company’s synthetic DNA technology with rapid turn-around and customizable constructs across viral and non-viral applications creates sales opportunities in research, genome editing, vaccine development, and therapeutics pipelines seeking faster prototyping and tailored payloads.

Therapy enablement By enabling design, manufacture, and supply of DNA and RNA constructs and delivery systems in-house, 4basebio can target biotechs and CROs accelerating cell and gene therapy programs and reducing supply-chain risk for nucleic acid payloads.

Niche partnerships Focus on applications for genome editing, vaccines, and DNA vaccine platforms suggests collaboration opportunities with mid-tier Biotech firms and specialty vaccine developers needing reliable, customizable constructs and delivery vectors.

Growth signals Revenue in the early multi-million range and a compact team indicate potential for scalable partnerships, co-development, or tiered service models with larger contract manufacturers seeking nimble, innovative nucleic acid solutions.